WASHINGTON — President Biden’s presumed pick to lead the National Institutes of Health, Monica Bertagnolli, will face a slew of questions on the multibillion-dollar agency’s spending and oversight in her upcoming confirmation battle.
This week, though, she won’t face what otherwise would have been Congress’s first round. A source close to the top cancer official, who announced her own cancer diagnosis last December, said she had to drop out of a scheduled Senate Appropriations Committee hearing Thursday because of previously scheduled routine cancer treatment, though she remains healthy.
The National Cancer Institute’s second-in-command, Douglas Lowy, will testify instead, alongside acting NIH director Lawrence Tabak and other senior NIH officials.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.